* Tonix Pharmaceuticals Holding Corp is expected to show a fall in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2024
* The Chatham New Jersey-based company is expected to report a 22.7% decrease in revenue to $3.083 million from $3.99 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Tonix Pharmaceuticals Holding Corp is for a loss of $2.93 per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp is $11.00, above its last closing price of $0.14.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -1.23 -3.27 -19.28 Missed -489
Mar. 31 0001 -12.38 -12.48 -5.76 Beat 53.8
Dec. 31 2023 -55.70 -52.59 -27.52 Beat 47.7
Sep. 30 2023 -47.04 -47.68 -58.56 Missed -22.8
Jan. -88.09 -88.16 -85.76 Beat 2.7
1 0001
Mar. 31 2023 -88.39 -97.00 -1.04 Missed -7.2
hundred
Dec. 31 2022 -1.08 -1.72 -1.12 Beat 34.9
hundred hundred hundred
Jan. 1 0001 -1.96 -2.04 -1.38 Beat 32.4
hundred hundred hundred
This summary was machine generated November 6 at 13:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。